Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + famitinib with or without short-course chemotherapy in PD-L1–positive advanced NSCLC (first-line)
ChiCTR2500115247Phase 4Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab and famitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Changzhou First People's Hospital. Primary endpoint: Progression-Free Survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500115247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115247.